Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Breast Neoplasms 19Neoplasm Metastasis 9Carcinoma, Non-Small-Cell Lung 5Prostatic Neoplasms 3Colorectal Neoplasms 3Brain Neoplasms 3Recurrence 2Pancreatic Neoplasms 2Neoplasms 2Melanoma 2Lymphoma, Non-Hodgkin 2Lymphoma 2Carcinoma, Renal Cell 2Advanced Cancer 2Unilateral Breast Neoplasms 1Thrombocytosis 1Solid Tumor 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Recurrent Ovarian High Grade Serous Adenocarcinoma 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Osteosarcoma 1Neuroblastoma 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Multiple Myeloma 1

Interventions

Nivolumab 8Paclitaxel 6Sirolimus 5Bevacizumab 5temsirolimus 4Pemetrexed 4Ipilimumab 4Docetaxel 4Carboplatin 4ARRY-334543 4Gemcitabine 3Erlotinib Hydrochloride 3olaparib 2linrodostat 2apatinib 2anlotinib 2abemaciclib 2Vorinostat 2Sunitinib 2Magnetic Resonance Spectroscopy 2Irinotecan 2Everolimus 2Doxorubicin 2Dasatinib 2Chlorogenic Acid 2Cetuximab 26-(6-(1-methyl-1H-pyrazol-4-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-ylsulfanyl)quinoline 2vorolanib 1vistusertib 1trametinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Advanced Cancer × abemaciclib × Clear all
NCT01394016 2024-09-19

A Phase 1 Study of LY2835219 In Participants With Advanced Cancer

Eli Lilly and Company

Phase 1 Completed
225 enrolled 31 charts

Advanced Cancer

NCT04071262 2021-09-21

A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Therapies in Japanese Participants With Advanced Cancer

Eli Lilly and Company

Phase 1 Completed
6 enrolled

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡